NeuroOne Medical Technologies Corporation (NMTC) Stock Forecast
Data as of Sep 19, 2026Healthcare · Current price $1.36 (0.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
NMTC vs Sector & Market
| Metric | NMTC | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +267.6% | +22243.4% | +21.5% |
| P/E Ratio | -5.84 | 3.77 | 38.34 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $11M | $11M | $12M | 3 |
| 2027-09-30 | $13M | $15M | $17M | 3 |
| 2028-09-30 | $20M | $23M | $25M | 2 |
| 2029-09-30 | $25M | $29M | $32M | 1 |
| 2030-09-30 | $30M | $35M | $39M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.14 | $-0.12 | $-0.10 | 2 |
| 2027-09-30 | $-0.10 | $-0.08 | $-0.07 | 2 |
| 2028-09-30 | $-0.03 | $-0.01 | $0.02 | 2 |
| 2029-09-30 | $0.06 | $0.07 | $0.08 | 1 |
| 2030-09-30 | $0.10 | $0.12 | $0.14 | 1 |
Frequently Asked Questions
What is the analyst consensus for NMTC?
The consensus among 2 analysts covering NeuroOne Medical Technologies Corporation (NMTC) is Buy with an average price target of $5.00.
What is the highest price target for NMTC?
The highest analyst price target for NMTC is $5.00.
What is the lowest price target for NMTC?
The lowest analyst price target for NMTC is $5.00.
How many analysts cover NMTC?
2 analysts have issued ratings for NeuroOne Medical Technologies Corporation in the past 12 months.
Is NMTC a buy or sell right now?
Based on 2 analyst ratings, NMTC has a consensus rating of Buy (2.00/5) with a +267.6% upside to the consensus target of $5.00.
What are the earnings estimates for NMTC?
Analysts estimate NMTC will report EPS of $-0.12 for the period ending 2026-09-30, with revenue estimated at $11M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.